Seeking Alpha

Alnylam Pharmaceuticals (ALNY) +9.4% premarket after the biotech firm says a study showed...

Alnylam Pharmaceuticals (ALNY) +9.4% premarket after the biotech firm says a study showed ALN-TTR02, a potential treatment for a genetic mutation of the transthyretin gene, reduced serum TTR protein levels in a way that was "rapid, dose dependent, durable, and specific after just a single dose."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)